STOCK TITAN

Coherus Biosciences Inc - CHRS STOCK NEWS

Welcome to our dedicated news page for Coherus Biosciences (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coherus Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coherus Biosciences's position in the market.

Rhea-AI Summary
Coherus BioSciences, Inc. announced that senior management will participate in several investor conferences, including Truist Securities BioPharma Symposium, UBS Biopharma Conference, and Evercore ISI HealthCONx Conference. The presentations will be webcasted and available on the Coherus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.73%
Tags
conferences
-
Rhea-AI Summary
Coherus BioSciences, Inc. will release its third quarter 2023 financial results on November 6, 2023, after market close. The management team will host a conference call and webcast to discuss the results and provide a business update. The conference call will take place on November 6, 2023, at 5:00 p.m. Eastern Time. Dial-in information and a personal PIN can be obtained by pre-registering through the provided link. The press release and related materials will be available on the company's website prior to the call, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, will be available on November 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.3%
Tags
conferences earnings
-
Rhea-AI Summary
Coherus BioSciences and Junshi Biosciences announced that the FDA has approved LOQTORZI™ (toripalimab-tpzi) for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). LOQTORZI demonstrated significant improvements in progression-free survival and overall survival compared to chemotherapy alone. It is the first FDA-approved treatment for NPC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
Rhea-AI Summary
Coherus BioSciences grants options to newly hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.16%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences resubmits BLA Supplement for UDENYCA ONBODY to FDA after resolving inspection findings at third-party filler.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.46%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences announces sales of CIMERLI® exceeding 100,000 doses and achieving 25% market share of the ranibizumab market* in August 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
none
Rhea-AI Summary
Coherus BioSciences supports Rare Cancer Day and bipartisan resolution to raise awareness for rare cancers like nasopharyngeal carcinoma (NPC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences announces presentation of three abstracts from its immuno-oncology pipeline at SITC Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
-
Rhea-AI Summary
FDA issues Complete Response Letter for UDENYCA® ONBODY™; No issues with clinical efficacy or safety; Toripalimab inspections completed
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.19%
Tags
Rhea-AI Summary
Coherus BioSciences grants options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Coherus Biosciences Inc

Nasdaq:CHRS

CHRS Rankings

CHRS Stock Data

251.35M
103.90M
1.35%
77.99%
20.8%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Redwood City

About CHRS

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp